atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference | Psychedelic Invest

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott…

Changing the landscape of R&D to build clinical success from the ground up

In this interview, NewsMedical talks to Amanda Jones at Revvity about the strategies and solutions available to revolutionize the landscape of R&D in clinical research.

May 28, 2024

Abbott, Medtronic partner on diabetes tech

Dive Brief: Abbott and Medtronic said Wednesday they will partner to create an integrated continuous glucose monitor that works with Medtronic’s diabetes technology. Abbott will

August 7, 2024

FDA announces rare disease hub in bid to streamline treatment paths

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.